🧾 What This Document Is

This is a 6-K filing, which is a report foreign companies like Israel-based PolyPid use to announce major news to the U.S. SEC and investors. Attached is a press release from March 31, 2026, announcing a huge step: they've started submitting their application to the FDA for their lead drug, D-PLEX₁₀₀. 👉 Why it matters: This isn't just news—it's the formal trigger for the FDA's clock to start on reviewing their potential new drug.

🏢 What The Company Does

In simple terms, PolyPid is a biopharmaceutical company trying to solve a major hospital problem: surgical site infections (SSIs). These are infections that develop where a patient had an operation, which can lead to serious complications, longer hospital stays, and higher costs. 👉 Their technology is designed to place a protective, antibiotic-releasing material directly into the surgical wound to prevent these infections from starting.

💊 The Drug: D-PLEX₁₀₀

This is PolyPid's lead product candidate, aimed at preventing SSIs specifically in patients undergoing colorectal surgery.

• How it works: It uses a proprietary delivery technology called Kynatrix to release the broad-spectrum antibiotic doxycycline directly at the surgical site.
• The key promise: It provides a prolonged (30-day), controlled release of the antibiotic right where it's needed most, aiming to create a high local concentration to fight bacteria, including some antibiotic-resistant strains.
• Proof it works: It recently succeeded in its Phase 3 SHIELD II trial, showing a statistically significant 60% relative risk reduction in SSIs (p=0.0013) after major colorectal surgery.

🚀 The Big Regulatory Move

PolyPid has officially initiated its New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). This is the formal request for permission to sell the drug.

• Submission Strategy: They are using the FDA's "rolling review" process under a Fast Track designation. This allows them to submit sections of the application as they're completed, rather than waiting to send everything at once.
• What's submitted now: They have sent in the Chemistry, Manufacturing and Controls (CMC) and nonclinical (lab and animal study) sections.
• What's next: They plan to submit the final clinical data section in the second quarter of 2026, completing the NDA.

💰 Financial & Business Context

While this filing isn't a financial report, the move is deeply tied to the company's financial future.

• The Goal: FDA approval would allow them to commercialize D-PLEX₁₀₀ in the U.S., which is the largest pharmaceutical market in the world.
• The Strategy: The press release notes that U.S. commercialization partnership negotiations are "on track." This means they are actively talking to larger pharma companies to help fund and manage the launch. 👉 Why it matters: A partnership would provide crucial funding and commercial expertise, reducing PolyPid's standalone financial risk and validating its technology.

🔮 What's Next & The Path Forward

The near-term path is clear and critical:

1. Complete the NDA: Submit the remaining clinical module in Q2 2026.
2. FDA Review: The FDA will then review the complete application. The Fast Track designation may lead to an accelerated review timeline.
3. Finalize a Partnership: Secure a deal with a commercial partner to prepare for a potential U.S. launch.
4. Potential Approval & Launch: If everything goes well, the drug could be approved and become available to patients.

⚖️ Big Picture: Strengths & Risks

👍 Promising Strengths:

• Strong Clinical Data: The 60% risk reduction from the Phase 3 trial is a powerful result.
• Regulatory Advantages: Has both Fast Track and Breakthrough Therapy designations from the FDA, signaling the agency sees this drug as addressing a serious unmet need.
• Clear Strategy: A focused plan on rolling submission and partnership talks.

⚠️ Key Risks:

• Regulatory Uncertainty: The FDA could still request more data, delay the review, or ultimately not approve the drug.
• Commercial Execution: Even with approval, successfully launching a new product requires significant investment and skill.
• Financing: As a clinical-stage company, it will need capital, likely through the partnership or other financing, to fund operations and launch.

🧠 The Analogy

Think of PolyPid as an inventor who has built a superior smart first-aid kit for post-surgical care. They've proven it works better than standard kits in a big test (the Phase 3 trial). Now, they've officially filed the paperwork with the national standards board (the FDA) to certify their invention. While the board reviews the plans, they're also talking to a major medical supply company (a commercial partner) to help mass-produce and sell the kits nationwide if they get the approval stamp.

📇 Key Contacts & People

• Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid
• Ori Warshavsky, PolyPid Ltd.
• Phone: 908-858-5995
• Email: [email protected]
• Investor Relations Contact: Arx Investor Relations, North American Equities Desk
• Email: [email protected]

🧩 Final Takeaway

PolyPid has moved from a successful clinical trial to the crucial regulatory approval phase for its promising anti-infection drug. The completion of the NDA submission in Q2 2026 and securing a commercial partner are the two major milestones that will determine its near-term future.